Clinical trial NCT02198924: Efficacy and Safety of Postoperative Intravenous Parecoxib Sodium Followed by Oral Celecoxib in Osteoarthritis Patients
Official title: A Study to Evaluate Efficacy and Safety of Postoperative Intravenous Parecoxib Sodium Followed by Oral Celecoxib Post Total Knee Arthroplasty in Osteoarthritis Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pain
Inflammation
Keywords: sequential administration
pain control
inflammation control
function recovery
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2014-07-24
Enrollment: 246
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In mainland China, knee Osteoarthritis (OA) is the leading cause of disability in older persons. Total knee arthroplasty (TKA) is now generally regarded by orthopaedic surgeons and patients as an effective treatment for end-stage knee OA in order to relieve pain, correct joint deformity and improve the life quality of patients.However, TKA has been called as one of the most painful Orthopedics surgery due to the weight bearing characteristics of knee joint and the high demand of functional exercise within the 6-8 weeks post operation. The targeted application of selective cyclooxygenase (COX) -2 inhibitor, such as Parecoxib or Celecoxib, can significantly reduce the level of inflammatory reaction one and two days postoperation . In addition, the perioperative administration of Celecoxib can directly or indirectly relieve postoperative pain, improve articular function and eventually augment life quality of the patients . Recently, effective treatment of post-operative pain with intravenous followed by oral COX-2 specific inhibitor has been demonstrated in many post-operative pain models . Significant morphine sparing effect and reduction of opioid distressed symptoms were also observed. In China, many surgeons have accept it as a routine strategy for controlling pain post TKA to sequentially give parecoxib 40 mg intravenously twice daily for the first 3 days post surgery and then Celecoxib 200mg orally twice daily. Although satisfactory results of this combination treatment on short-term pain reduction and functional improvement has been observed in clinical practice, high quality evidence is still lacking to prove its effect on the medium or long-term functionality recovery. This study is being conducted to investigate the combination regimen with intravenous parecoxib followed by oral celecoxib for post-surgical analgesic treatment in osteoarthritis patients undergoing total knee arthroplastic (TKA) surgery. Subjects will receive double-blinded study medication consisting of parecoxib injection in analgesic doses or matching placebo followed by oral celecoxib in acute pain doses or matching placebo in a double-blinded fashion. The hypothesis is subjects treated with parecoxib/celecoxib will consume less morphine over the first 24 hours of postoperation period, achieve improved pain control over study period, a quicker return to functionality, and has less opioid adverse events than those treated with opioids alone over 6-week recovery phase.

Detailed description: Total knee arthroplasty (TKA), though generally regarded as an effective treatment for end-stage knee OA, has been called as "one of the most painful orthopedics surgeries" due to the weight bearing characteristics of knee joint and the high demand of functional exercise within the 6-8 weeks post operation.

Parecoxib and Celecoxib have been found to be able to relieve postoperative pain, spare opioid use, improve articular function and eventually augment life quality of the patients after TKA. In China, therefore, many surgeons have accept it as a routine strategy for controlling pain post TKA to sequentially use Parecoxib and then Celecoxib. However, high quality evidence is still lacking to prove its effect on the medium or long-term functionality recovery.

This multicenter, double blind, parallel-group randomized study, therefore, is aiming to evaluate efficacy and safety of postoperative intravenous Parecoxib sodium followed by oral Celecoxib in OA patients undergoing TKA. The hypothesis is that compared to placebo with opioids as rescue treatment, sequential use of Parecoxib/Celecoxib can achieve not only less morphine consumption over postoperatively 2 weeks, but also better pain control, quicker functional recovery, and less opioid related adverse events over 6-week recovery phase.

The primary objective of this study is to evaluate the morphine-sparing effects of the combination treatment with Parecoxib and Celecoxib versus placebo in subjects undergoing TKA. The secondary objective is to compare the effects of the combination treatment versus placebo on pain relief, inflammation control and functional rehabilitation after TKA. Total 86 subjects per group would have 90% power in detecting 100 mg or more in mean difference of morphine use on Day 14 between the two groups, assuming a common standard deviation of 200, and a two-sided alpha level of 0.05. This would result in a total 172 subjects. In consideration of 30% drop outs, 246 subjects would be adequate for the study. All subjects who meet the study inclusion and exclusion criteria will be randomly assigned in a 1:1 ratio to either Parecoxib/Celecoxib group or placebo group. The allocation or randomization will be study site based.Data will be collected using an Electronic Data Capture (EDC) under a strict intent-to-treat methodology, i.e., all the data of any Inform Consent Form signed subjects will be included in the study database.All subjects will be recruited from 4 study centers in China. The study will consist of 3 phases: an initial screening phase which must be completed within 30 days prior to randomization; a 6-week double blind treatment phase; and a 6 week follow up phase. A two-week wash-out procedure will be required before randomization for the patients with previous use of nonsteroidal antiinflammatory drug (NSAID) or COX-2 specific inhibitors.Variables considered continuous will be presented by descriptive statistics: number, mean, standard deviation, median, minimum, and maximum; and analyzed using parametric or non-parametric ANOVA, as appropriate. Variables considered categorical will be tabulated by frequency counts and percentages; and analyzed using Chi-square test or Fisher's exact tests. All the statistical tests will be two-sided with alpha=0.05, i.e., a p value \<= 0.05 would be considered statistically significant.

Eligibility criteria: Inclusion Criteria:

1. The subject is scheduled to undergo elective unilateral total knee arthroplasty because of OA, performed under a standardized regimen of general anesthesia, as specified in this protocol.
2. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
3. The subject is a male or female over 18 years of age.
4. Subjects of childbearing potential must agree to use an effective method of contraception throughout the study and for 42 days after the last dose of assigned treatment.
5. Total duration of the surgical procedure is four hours or less.
6. ASA grade 1-3 subjects.
7. Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, standardized rehabilitation scheme, and other study procedures.
8. The subject is in satisfactory health as determined by the investigator on the basis of medical history and physical exam.
9. The subject must demonstrate sufficient psychomotor dexterity and cognitive capacity to use intravenous (IV) patient-controlled analgesia(PCA).
10. The subject who live near to the hospital may be considered prior for the concern of convenient and sufficient follow-up.

    -

Exclusion Criteria:

1. The subject requires a revision to previous knee arthroplasty and/or is having a bilateral knee arthroplasties.
2. The subject requires an emergency knee arthroplasty.
3. Subject uses opioids more than three days/ week prior to operation unless they discontinue the opioids two months prior to screen.
4. Subject has a known hypersensitivity to COX-2 specific inhibitors, sulfonamides, lactose, NSAIDs, opioids or acetaminophen/paracetamol.
5. The subject has a history of arthritis:, chronic pain, metastasis, and Paget's disease.
6. The subject received any investigational medication within 30 days prior to the first dose of study medication.
7. The subject has any known laboratory abnormality, which in the opinion of the investigator, would contraindicate study participation ≧1.5 times the upper limit of the normal reference range.
8. The subject has an active malignancy of any type, or history of a malignancy (Subjects who have a history of basal cell carcinoma that has been successfully treated can be entered into the study.
9. Subject had any condition, which could preclude use of NSAIDs or COX-2 specific inhibitors.
10. The subject has active or suspected esophageal, gastric, pyloric channel, or duodenal ulceration history.
11. The subject has received warfarin or other anticoagulants during the 30 days preceding the first dose of study medication.
12. Subject is anticipated to require or requires treatment with lithium.
13. Subject is American Society of Anesthesiologists(ASA) grade 4-5.
14. The subject has a history of a psychiatric disorder requiring new or changing treatment
15. The subject has a history of uncontrolled chronic disease or a concurrent clinically significant illness, medical condition.
16. The subject has any cognitive impairment or other characteristics that would in the investigator's opinion preclude study participation or compliance with protocol mandated procedures.
17. Subject has a history of asthma or bronchospasm, which requires treatment with glucocorticoids.
18. Subject had a history of alcohol, analgesic or narcotic abuse.
19. Subject has been previously randomized into the study
20. Subjects who are investigational site staff members or relatives of those site staff
21. Participation in other studies within 3 months before the current study begins and/or during study participation
22. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation.
23. Pregnant females, breastfeeding females, or males and females of childbearing potential not using effective contraception.

    -

Primary outcomes:
measure: Total narcotic use
timeFrame: Post-operative 2 WEEKS
Secondary outcomes:
measure: Knee Society Score
timeFrame: post-operation 6 weeks
measure: Western Ontario and McMaster Universities Arthritis(WOMAC) Index
timeFrame: prior to operation and at 2w,4w and 6w post operation
measure: Knee Society Score
timeFrame: prior to operation and at 2w and 4w post operation
measure: Total Morphine use
timeFrame: over the first 24 hours postsurgical period
measure: Total narcotic use
timeFrame: 72h, 4w, 6w post operation
measure: Visual Analogue Scale
timeFrame: prior to operation and at 24h, 48h, 72h, 2w, 4w and 6w post operation
measure: EuroQol (EQ-5D) Score
timeFrame: prior to operation and 72h, 2w, 4w and 6w post operation
Other outcomes:
measure: Knee circumference
timeFrame: prior to operation and at 72h, 2w, 4w and 6w post operation
measure: skin temperature
timeFrame: prior to operation and at 72h, 2w, 4w and 6w post operation
measure: Erythrocyte sedimentation rate(ESR)
timeFrame: prior to operation and at 72h, 2w, 4w and 6w post operation
measure: C-Reactive Protein，CRP
timeFrame: prior to operation and at 72h, 2w, 4w and 6w post operation
measure: interleukin-6 concentration in Synovial fluid
timeFrame: 0h, 24h and 48h post operation
measure: interleukin-8 concentration in Synovial fluid
timeFrame: 0h, 24h and 48h post operation
measure: interleukin-10 Synovial fluid concentration
timeFrame: 0h, 24h and 48h post operation
measure: prostaglandin E2 concentration in Synovial fluid
timeFrame: 0h, 24h and 48h post operation
measure: interleukin-6 concentration in Peripheral blood
timeFrame: prior to operation and at 72h, 2w, 4w and 6w post operation
measure: interleukin-8 concentration in Peripheral blood
timeFrame: prior to operation and at 72h, 2w, 4w and 6w post operation
measure: interleukin-10 concentration in Peripheral blood
timeFrame: prior to operation and at 72h, 2w, 4w and 6w post operation
measure: prostaglandin E2 concentration in Peripheral blood
timeFrame: prior to operation and at 72h, 2w, 4w and 6w post operation
measure: blood coagulation
timeFrame: prior to operation and at 72h, 2w, 4w and 6w post operation
measure: The nature, incidence, duration, and severity of adverse events
timeFrame: until 6w post operation
measure: Discontinuation due to adverse events
timeFrame: until 6w post operation
measure: Adverse events
timeFrame: during and after trial medication discontinuation
measure: complete blood count
timeFrame: 2 weeks post operation
measure: blood chemistry parameters
timeFrame: 6w post operation
measure: urinalysis test
timeFrame: 2 weeks post operation
Locations:
city: Beijing
country: China
facility: Peking Union Medical College Hospital
Study officials:
affiliation: Peking Union Medical College Hospital
name: Xisheng Weng, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Carr AJ, Robertsson O, Graves S, Price AJ, Arden NK, Judge A, Beard DJ. Knee replacement. Lancet. 2012 Apr 7;379(9823):1331-40. doi: 10.1016/S0140-6736(11)60752-6. Epub 2012 Mar 6.
citation: Du Q, Ge HJ, Zhu PF. Effects of perioperative analgesia on postoperative inflammatory response. Int J Anesth Resus., 2007, 28(1):48-53.
citation: Holm B, Kristensen MT, Bencke J, Husted H, Kehlet H, Bandholm T. Loss of knee-extension strength is related to knee swelling after total knee arthroplasty. Arch Phys Med Rehabil. 2010 Nov;91(11):1770-6. doi: 10.1016/j.apmr.2010.07.229.
citation: Honsawek S, Deepaisarnsakul B, Tanavalee A, Sakdinakiattikoon M, Ngarmukos S, Preativatanyou K, Bumrungpanichthaworn P. Relationship of serum IL-6, C-reactive protein, erythrocyte sedimentation rate, and knee skin temperature after total knee arthroplasty: a prospective study. Int Orthop. 2011 Jan;35(1):31-5. doi: 10.1007/s00264-010-0973-0. Epub 2010 Feb 21.
citation: Rasmussen GL, Steckner K, Hogue C, Torri S, Hubbard RC. Intravenous parecoxib sodium foracute pain after orthopedic knee surgery. Am J Orthop (Belle Mead NJ). 2002 Jun;31(6):336-43.
citation: Hubbard RC, Naumann TM, Traylor L, Dhadda S. Parecoxib sodium has opioid-sparing effects in patients undergoing total knee arthroplasty under spinal anaesthesia. Br J Anaesth. 2003 Feb;90(2):166-72. doi: 10.1093/bja/aeg038.
citation: Nussmeier NA, Whelton AA, Brown MT, Joshi GP, Langford RM, Singla NK, Boye ME, Verburg KM. Safety and efficacy of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib after noncardiac surgery. Anesthesiology. 2006 Mar;104(3):518-26. doi: 10.1097/00000542-200603000-00020.
citation: Zhuang Q, Tao L, Lin J, Jin J, Qian W, Bian Y, Li Y, Dong Y, Peng H, Li Y, Fan Y, Wang W, Feng B, Gao N, Sun T, Lin J, Zhang M, Yan S, Shen B, Pei F, Weng X. Postoperative intravenous parecoxib sodium followed by oral celecoxib post total knee arthroplasty in osteoarthritis patients (PIPFORCE): a multicentre, double-blind, randomised, placebo-controlled trial. BMJ Open. 2020 Jan 9;10(1):e030501. doi: 10.1136/bmjopen-2019-030501.
citation: Zhuang Q, Bian Y, Wang W, Jiang J, Feng B, Sun T, Lin J, Zhang M, Yan S, Shen B, Pei F, Weng X. Efficacy and safety of Postoperative Intravenous Parecoxib sodium Followed by ORal CElecoxib (PIPFORCE) post-total knee arthroplasty in patients with osteoarthritis: a study protocol for a multicentre, double-blind, parallel-group trial. BMJ Open. 2016 Sep 8;6(9):e011732. doi: 10.1136/bmjopen-2016-011732.